Erythromycin Ophthalmic Ointment USP, 0.5%

Manufacturer
A-S Medication Solutions
Effective date
2023-02-04
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
16
Source
legacy-cache
Hydrated at
2026-08-01 21:37:58

Label at a glance#

ProductErythromycin
Active ingredientERYTHROMYCIN
Label structure10 sections

Indications and uses

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrh...

Dosage and administration

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Opthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. Th...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Sterile

Rx only

DESCRIPTION:

DESCRIPTION SECTION

Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*, 13S*, 14R*)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethyl-amino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione)) is an antibiotic produced from a strain of Streptomyces erythraeus.

It has the following structural formula:

Structural Formula
Structural Formula

Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

MICROBIOLOGY SECTION

Microbiology: Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections:

Streptococcus pyogenes (group A β-hemolytic)

Alpha-hemolytic streptococci (viridans group)

Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)

Streptococcus pneumoniae

Mycoplasma pneumoniae (Eaton Agent, PPLO)

Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)

Treponema pallidum

Corynebacterium diphtheriae

Neisseria gonorrhoeae

Chlamydia trachomatis

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis.

The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

INFORMATION FOR PATIENTS SECTION

Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers, or other source.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, Impairment of Fertility: Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.

PREGNANCY SECTION

Pregnancy: Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers: Caution should be exercised when erythromycin is administered to a nursing woman.

GERIATRIC USE SECTION

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Opthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection.

For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Product: 50090-0248

NDC: 50090-0248-0 3.5 g in a TUBE / 1 in a CARTON

Erythromycin

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label Image
Label Image

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
50090-0248-02023-02-07C16284748780-1f386c649-c8a5-0266-e053-dadaa90a7c1aErythromycin Ophthalmic Ointment USP, 0.5%
50090-0248-02023-01-30C16284748780-1f386c649-c8a5-0266-e053-dadaa90a7c1aErythromycin Ophthalmic Ointment USP, 0.5%

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50090-0248-0GM - Gram50090-02482853f1f7-508a-4062-9fe0-098aa15b451f12018-08-13
17478-070-31GM - Gram17478-070fd4abc07-1c54-4954-b3fd-2d91b9875c2e12012-07-24
17478-070-35GM - Gram17478-0700e89b274-9b8a-41f2-865f-62c815064b6312012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50090-024850090-0248-0
17478-070

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
ERYTHROMYCIN63937KV33DACTIB
mineral oilT5L8T28FGPIACT
petrolatum4T6H12BN9UIACT

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064030-001ERYTHROMYCINERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064030-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1884e616aacf4f…
2026-08-18 06:07:402026-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-1887673890dc5c…
2021-03-12 10:30 UTC2021-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183f01610625f2…
2019-09-15 20:21 UTC2019-09A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18b00525d2431f…
2019-07-19 19:46 UTC2019-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183f0d92c62455…
2023-05-13 08:27 UTC2023-05A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18053a50430f4f…
2023-01-26 05:58 UTC2023-01A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064030-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1996-07-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064030-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064030-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064030-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064030-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064030-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064030-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064030-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064030-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064030-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064030-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064030-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064030-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064030-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064030-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064030-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064030-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064030-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064030-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064030-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064030-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064030-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064030-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064030-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064030-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064030-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064030-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064030-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064030-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064030-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064030-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064030-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064030-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064030-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064030-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064030-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064030-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064030-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064030-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064030-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064030-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
2fd0d3ba-fcfb-4d45-9ef6-bdf8ffa523eefb1e8f2c-3f89-4a5b-a1fd-2fb88e4733412024-03-21Adverse reactionsExact identifier
spl set id: fb1e8f2c-3f89-4a5b-a1fd-2fb88e473341

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.